# Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

> **NCT00871338** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 284 (actual)

## Conditions studied

- Neisseria Meningitidis
- Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** GSK2197870A
- **BIOLOGICAL:** Prevenar™
- **BIOLOGICAL:** Menitorix™
- **BIOLOGICAL:** Pediacel™
- **BIOLOGICAL:** Menjugate™

## Key facts

- **NCT ID:** NCT00871338
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-24
- **Primary completion:** 2010-03-31
- **Final completion:** 2010-12-09
- **Target enrollment:** 284 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871338, "Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00871338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*